Published in

Nature Research, Scientific Reports, 1(12), 2022

DOI: 10.1038/s41598-022-15547-2

Links

Tools

Export citation

Search in Google Scholar

Characterisation of the blood RNA host response underpinning severity in COVID-19 patients

Journal article published in 2022 by Giselle D’Souza, Pérez del Molino Bernal Marisa, Irene Rivero Calle, Hugo Pérez-Freixo, Álvarez Escudero Julián, Carral García María Victoria, Bello Paderne Xabier, Samuel Nichols, Ben García Miriam, Costa Alcalde José Javier, Cebey López Miriam, Ortensia Vito ORCID, Currás Tuala María José, Conde Pájaro Mónica, Carral García María Victoria and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

AbstractInfection with SARS-CoV-2 has highly variable clinical manifestations, ranging from asymptomatic infection through to life-threatening disease. Host whole blood transcriptomics can offer unique insights into the biological processes underpinning infection and disease, as well as severity. We performed whole blood RNA Sequencing of individuals with varying degrees of COVID-19 severity. We used differential expression analysis and pathway enrichment analysis to explore how the blood transcriptome differs between individuals with mild, moderate, and severe COVID-19, performing pairwise comparisons between groups. Increasing COVID-19 severity was characterised by an abundance of inflammatory immune response genes and pathways, including many related to neutrophils and macrophages, in addition to an upregulation of immunoglobulin genes. In this study, for the first time, we show how immunomodulatory treatments commonly administered to COVID-19 patients greatly alter the transcriptome. Our insights into COVID-19 severity reveal the role of immune dysregulation in the progression to severe disease and highlight the need for further research exploring the interplay between SARS-CoV-2 and the inflammatory immune response.